Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MedImmune -- Ignore unavailable to you. Want to Upgrade?

To: BossMan who wrote (111)	4/22/1998 7:18:00 PM
From: James Mortensen	Read Replies (1) \| Respond to of 416

$0.44 profit vs. $0.23 estimated. After hrs. trading was up over $58. GAITHERSBURG, Md., April 22 /PRNewswire/ -- MedImmune, Inc. (Nasdaq: MEDI - news) today reported net income for the quarter ended March 31, 1998 of $13.2 million or $0.44 per share on a diluted basis compared to a net loss of $14.3 million or $0.65 per share on a diluted basis for the same period in 1997. Total revenues for the quarter increased nearly six-fold to $59.3 million from $10.1 million in first quarter 1997. In first quarter 1998, sales of RespiGam(R) (Respiratory Syncytial Virus Immune Globulin Intravenous (Human)) increased more than six-fold to $32.1 million from $5.2 million in first quarter 1997 and sales of CytoGam(R) (Cytomegalovirus Immune Globulin Intravenous (Human)) in the quarter more than doubled to $10.8 million from $5.0 million in first quarter 1997. Regards, Jim